A new Ethereum privacy pool design using Flock technology generated a withdrawal proof in just 28.6 milliseconds, about 28 times faster than previous methods. This approach batches SHA-256 circuit steps in smaller units, improving speed while maintaining post-quantum security. The system also includes a recovery method for deposits if older cryptography becomes vulnerable to quantum attacks, ensuring long-term security. This advancement could enhance privacy and security for Ethereum users facing future quantum computing threats.
Ethereum privacy pool innovation is marked by a withdrawal proof time of just 28.6 milliseconds, showcasing a significant speed improvement. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell today. Notable movers include SAND at Rp1.058 with a 2.80% decline and 65% buy order activity, FIL at Rp18.576 down 2.65% with 61% buy orders, and UNI at Rp132.893 up 2.26% with 86% sell orders.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
